Back to top
more

Zimmer Biomet (ZBH)

(Real Time Quote from BATS)

$109.27 USD

109.27
414,696

+1.09 (1.01%)

Updated Nov 11, 2024 12:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zimmer (ZBH) Down 7.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.

Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic

by Zacks Equity Research

Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.

Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up

by Zacks Equity Research

Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 13.25% and 5.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.

Cerner (CERN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.

Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

McKesson (MCK) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.

PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at Diagnostics segment.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance by net dialysis and the related lab patient service segment are likely to have aided DaVita's (DVA) top line in the first quarter.

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.

    DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.

    Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?

    by Zacks Equity Research

    Ecolab's (ECL) first-quarter results are likely to reflect strength in the Global Healthcare and Life Sciences segment.

    Debanjana Dey headshot

    Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

    by Debanjana Dey

    Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

    Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

    What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) first-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.

    Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite

    by Zacks Equity Research

    Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.

    Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA

    by Zacks Equity Research

    For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.

    Why Is Zimmer (ZBH) Down 1.4% Since Last Earnings Report?

    by Zacks Equity Research

    Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis

    by Zacks Equity Research

    In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.